Faculty of Medicine, University of Porto, Porto, Portugal.
Department of Pediatrics, Centro Hospitalar Universitário de São João, Porto, Portugal.
Eur J Pediatr. 2023 Aug;182(8):3433-3443. doi: 10.1007/s00431-023-05031-y. Epub 2023 Jun 1.
Platelet transfusions (PTx) are the principal approach for treating neonatal thrombocytopenia, a common hematological abnormality affecting neonates, particularly preterm infants. However, evidence about the outcomes associated with PTx and whether they provide clinical benefit or harm is lacking. The aim of this systematic review and meta-analysis is to assess the association between PTx in preterm infants and mortality, major bleeding, sepsis, and necrotizing enterocolitis (NEC) in comparison to not transfusing or using different platelet count thresholds for transfusion. A broad electronic search in three databases was performed in December 2022. We included randomized controlled trials, and cohort and case control studies of preterm infants with thrombocytopenia that (i) compared treatment with platelet transfusion vs. no platelet transfusion, (ii) assessed the platelet count threshold for PTx, or (iii) compared single to multiple PTx. We conducted a meta-analysis to assess the association between PTx and mortality, intraventricular hemorrhage (IVH), sepsis, and NEC and, in the presence of substantial heterogeneity, leave-one-out sensitivity analysis was performed. We screened 625 abstracts and 50 full texts and identified 18 reports of 13 eligible studies. The qualitative analysis of the included studies revealed controversial results as several studies showed an association between PTx in preterm infants and a higher risk of mortality, major bleeding, sepsis, and NEC, while others did not present a significant relationship. The meta-analysis results suggest a significant association between PTx and mortality (RR 2.4, 95% CI 1.8-3.4; p < 0.0001), as well as sepsis (RR 4.5, 95% CI 3.7-5.6; p < 0.0001), after a leave-one-out sensitivity analysis. There was also found a significant correlation between PTx and NEC (RR 5.2, 95% CI 3.3-8.3; p < 0.0001). As we were not able to reduce heterogeneity in the assessment of the relationship between PTx and IVH, no conclusion could be taken. Conclusion: Platelet transfusions in preterm infants are associated to a higher risk of death, sepsis, and NEC and, possibly, to a higher incidence of IVH. Further studies are needed to confirm these associations, namely between PTx and IVH, and to define the threshold from which PTx should be given with less harm effect. What is Known: • Platelet transfusions are given to preterm infants with thrombocytopenia either to treat bleeding or to prevent hemorrhage. • Lack of consensual criteria for transfusion. What is New: • A significant association between platelet transfusions and mortality, sepsis, and NEC.
血小板输注(PTx)是治疗新生儿血小板减少症的主要方法,这是一种常见的血液学异常,影响新生儿,尤其是早产儿。然而,缺乏关于 PTx 相关结局的证据,也不清楚其是否具有临床获益或危害。本系统评价和荟萃分析旨在评估早产儿中 PTx 与死亡率、主要出血、败血症和坏死性小肠结肠炎(NEC)之间的关联,并与不输血或使用不同血小板计数阈值输血进行比较。我们于 2022 年 12 月在三个数据库中进行了广泛的电子检索。我们纳入了比较血小板输注与不输血、评估血小板输注阈值或比较单次与多次 PTx 的治疗血小板减少症的早产儿的随机对照试验和队列研究以及病例对照研究。我们进行了荟萃分析,以评估 PTx 与死亡率、脑室出血(IVH)、败血症和 NEC 之间的关联,如果存在显著异质性,则进行逐一剔除敏感性分析。我们筛选了 625 篇摘要和 50 篇全文,确定了 13 项符合条件的研究的 18 份报告。纳入研究的定性分析显示结果存在争议,因为一些研究表明早产儿中 PTx 与死亡率、主要出血、败血症和 NEC 风险增加有关,而其他研究则没有显示出显著的相关性。逐一剔除敏感性分析后,荟萃分析结果表明 PTx 与死亡率(RR 2.4,95%CI 1.8-3.4;p<0.0001)以及败血症(RR 4.5,95%CI 3.7-5.6;p<0.0001)之间存在显著关联。还发现 PTx 与 NEC(RR 5.2,95%CI 3.3-8.3;p<0.0001)之间存在显著相关性。由于我们无法降低评估 PTx 与 IVH 之间关系的异质性,因此无法得出结论。结论:早产儿中血小板输注与死亡、败血症和 NEC 的风险增加有关,并且可能与 IVH 的发生率增加有关。需要进一步的研究来证实这些关联,特别是 PTx 与 IVH 之间的关联,并确定应给予血小板输注的阈值,以减少危害效应。已知:•血小板输注用于治疗血小板减少症的早产儿,要么是为了治疗出血,要么是为了预防出血。•缺乏输血的共识标准。新内容:•血小板输注与死亡率、败血症和 NEC 之间存在显著关联。